Ajinomoto and Bright Peak Therapeutics announced a research collaboration and exclusive license agreement to incorporate AJICAP®, Ajinomoto’s proprietary site-specific bioconjugation technology, for the development of Bright Peak Immunocytokines.
Bright Peak uses a novel ligation technology to chemically synthesize therapeutic cytokines by ligating together customized peptide segments. This proprietary platform provides flexibility to both tune and enhance cytokine biology through affinity modification and orthogonal, site-specific conjugation, respectively. AJICAP is a proprietary site-specific bioconjugation technology compatible with commonly used antibody isotypes.
As part of the collaboration and license agreement with Ajinomoto, the AJICAP technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines. These Immunocytokines will allow tissue- and cell-specific targeting of the cytokine payload with the added potential for synergistic efficacy through potency-enhancing avidity effects. As part of the agreement, Bright Peak will receive exclusive worldwide rights to use the AJICAP technology for the conjugation of certain cytokine payloads, including but not limited to interleukin-2 (IL-2). The agreement is for the development of multi Immunocytokine molecules. Under the terms of the agreement, Bright Peak will make an exclusivity payment and Ajinomoto Co. is eligible to receive development, regulatory and commercial milestone payments as well as royalties on commercial sales.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"We are delighted to announce the collaboration with Ajinomoto Co.to develop our proprietary Immunocytokines using AJICAP technology. It is a natural extension of Bright Peak’s chemical synthesis technology platform. The AJICAP conjugation technology is ideally suited to conjugate our enhanced cytokines as payloads to antibodies in the cancer and autoimmune field” said Dr. Sef Kurstjens President and CEO of Bright Peak Therapeutics, Inc.
"Ajinomoto Co. and Ajinomoto Bio-Pharma Services are very excited to collaborate with Bright Peak in the development of targeted Immunocytokines. The ability to direct potent, homogeneous immune-signaling molecules to tumors and the tumor microenvironment may provide enhanced antitumor clinical benefit through immune cell cytotoxic activity. The combination of Bright Peak’s cytokine payloads with Ajinomoto Co.’s AJICAP opens up a wide range of oncology applications and may be harnessed to provide a clinical benefit to patients,” Dr. Tatsuya Okuzumi, Associate General Manager, Research and Business Planning Department, Ajinomoto said.